9 METERS BIOPHARMA, INC.

$ Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-Q Financial Statement

#000155198619000114 Filed on November 07, 2019

Income Statement

Concept	2019 Q4	2019 Q3	2018 Q4

Balance Sheet

Concept	2019 Q4	2019 Q3	2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.590M	$8.860M	$5.730M
YoY Change	-19.9%	9.25%	1232.56%
Cash & Equivalents	$4.593M	$8.864M	$5.729M
Short-Term Investments
Other Short-Term Assets	$640.0K	$860.0K	$680.0K
YoY Change	-5.88%	62.26%	1260.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$5.223M	$9.720M	$6.414M
YoY Change	-18.56%	12.53%	752.63%
LONG-TERM ASSETS
Property, Plant & Equipment	$25.42K	$28.47K	$35.10K
YoY Change	-27.56%	-29.25%	-13.79%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$5.580K	$5.580K	$5.580K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$73.83K	$90.32K	$40.68K
YoY Change	81.52%	97.15%	-12.12%
TOTAL ASSETS
Total Short-Term Assets	$5.223M	$9.720M	$6.414M
Total Long-Term Assets	$73.83K	$90.32K	$40.68K
Total Assets	$5.297M	$9.810M	$6.454M
YoY Change	-17.93%	12.98%	708.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.890M	$3.057M	$3.619M
YoY Change	7.5%	6.04%	36.11%
Accrued Expenses	$4.748M	$1.863M	$826.3K
YoY Change	474.56%	712.21%	-29.99%
Deferred Revenue
YoY Change
Short-Term Debt	$3.180M	$3.880M	$5.200M
YoY Change	-38.85%	-25.24%	282.35%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$14.91M	$13.13M	$10.11M
YoY Change	47.44%	58.09%	-22.04%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.91M	$13.13M	$10.11M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$14.91M	$13.13M	$10.11M
YoY Change	47.44%	58.19%	281.63%
SHAREHOLDERS EQUITY
Retained Earnings	-$70.56M	-$61.66M	-$43.52M
YoY Change	62.16%	56.88%	124.85%
Common Stock	$3.948K	$3.589K	$2.609K
YoY Change	51.32%	38.14%	-78.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$9.614M	-$3.315M	-$3.659M
YoY Change
Total Liabilities & Shareholders Equity	$5.297M	$9.810M	$6.454M
YoY Change	-17.93%	12.98%	708.3%

Cashflow Statement

Concept	2019 Q4	2019 Q3	2018 Q4

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	25818495	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24269266	shares
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35883953	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	32401624	shares
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	1617607	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	5006309	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	-3314923	USD
CY2018Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.10
CY2018Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2019Q2	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. Areas of the financial statements where estimates may have the most significant effect include accrued expenses, share-based compensation, valuation of the derivative liability and warrant liabilities, valuation allowance for income tax assets and management’s assessment of the Company’s ability to continue as a going concern. Changes in the facts or circumstances underlying these estimates could result in material changes and actual results could differ from these estimates.</font></div></div>
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Document Period End Date DocumentPeriodEndDate	2019-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001551986
CY2019Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	35883953	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2019Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	2.025
	us-gaap	Stock Issued1 StockIssued1	9229819	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	30064	USD
	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	9229819	USD
CY2018Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	16137661	USD
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11475255	USD
CY2019Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	8744501	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-12174614	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	7846256	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	3459176	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	380800	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-3659064	USD
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2018Q1	innt	Adjustments To Additional Paid In Capital Warrant Issued To Placement Agents AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToPlacementAgents	913000	USD
CY2018Q1	innt	Adjustments To Additional Paid In Capital Warrant Issued To Placement Agents AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToPlacementAgents	913000	USD
CY2019Q3	innt	Capital Stock Authorized CapitalStockAuthorized	360000000	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	INNOVATE BIOPHARMACEUTICALS, INC.
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Small Business EntitySmallBusiness	true
CY2018Q4	innt	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	58151	USD
CY2019Q3	innt	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	1268132	USD
CY2018Q3	innt	Accrued Milestone Fees AccruedMilestoneFees	0	USD
	innt	Accrued Milestone Fees AccruedMilestoneFees	0	USD
CY2019Q3	innt	Accrued Milestone Fees AccruedMilestoneFees	300000	USD
	innt	Accrued Milestone Fees AccruedMilestoneFees	300000	USD
CY2019Q1	innt	Adjustments To Additional Paid In Capital Allocation Of Warrants To Liabilities AdjustmentsToAdditionalPaidInCapitalAllocationOfWarrantsToLiabilities	1970000	USD
CY2019Q2	innt	Adjustments To Additional Paid In Capital Allocation Of Warrants To Liabilities AdjustmentsToAdditionalPaidInCapitalAllocationOfWarrantsToLiabilities	1360000	USD
CY2019Q2	innt	Class Of Warrant Or Right Purchase Price Of Each Additional Warrant ClassOfWarrantOrRightPurchasePriceOfEachAdditionalWarrant	0.125
CY2019Q2	innt	Class Of Warrant Or Right Restriction Period ClassOfWarrantOrRightRestrictionPeriod	P45D
	innt	Commissions Payable For Warrants Exercised CommissionsPayableForWarrantsExercised	87152	USD
	innt	Commissions Payable For Warrants Exercised CommissionsPayableForWarrantsExercised	0	USD
	innt	Convertible Promissory Notesbeneficial Conversion Feature ConvertiblePromissoryNotesbeneficialConversionFeature	3077887	USD
	innt	Convertible Promissory Notesbeneficial Conversion Feature ConvertiblePromissoryNotesbeneficialConversionFeature	0	USD
CY2018Q3	innt	Estimated Clinical Trial Data Management Fee EstimatedClinicalTrialDataManagementFee	1100000	USD
CY2018Q1	innt	Exchange Ratio In Connection With Merger ExchangeRatioInConnectionWithMerger	0.37686604
	innt	Gain Losson Extinguishmentof Derivative Liability GainLossonExtinguishmentofDerivativeLiability	0	USD
	innt	Gain Losson Extinguishmentof Derivative Liability GainLossonExtinguishmentofDerivativeLiability	370000	USD
CY2018Q1	innt	Net Proceeds From Issuance Of Common Stock After Deducting Stock Issuance Costs NetProceedsFromIssuanceOfCommonStockAfterDeductingStockIssuanceCosts	16500000	USD
	innt	Noncash Addition Of Deferred Offering Costs NoncashAdditionOfDeferredOfferingCosts	0	USD
	innt	Noncash Addition Of Deferred Offering Costs NoncashAdditionOfDeferredOfferingCosts	151137	USD
	innt	Noncash Addition Of Derivative Liability NoncashAdditionOfDerivativeLiability	0	USD
	innt	Noncash Addition Of Derivative Liability NoncashAdditionOfDerivativeLiability	1281000	USD
CY2019Q3	innt	Number Of Stock Option Plans NumberOfStockOptionPlans	2	plan
CY2018Q1	innt	Number Of Warrants Issued NumberOfWarrantsIssued	1400000	shares
CY2017Q4	innt	Operating Lease Annual Rental Payments OperatingLeaseAnnualRentalPayments	60000	USD
CY2018Q4	innt	Operating Lease Monthly Rental Payments OperatingLeaseMonthlyRentalPayments	5000	USD
	innt	Payments To Executives PaymentsToExecutives	1100000	USD
CY2018Q1	innt	Placement Agent Fees PlacementAgentFees	1600000	USD
CY2014	innt	Royalties Payment Expiration Requirement RoyaltiesPaymentExpirationRequirement	P10Y
CY2018Q3	innt	Saleof Stock Shares Issuable Upon Exerciseof Warrant SaleofStockSharesIssuableUponExerciseofWarrant	2051771	shares
CY2018Q3	innt	Saleof Stock Shelf Registration Maximum Equity Offering Price SaleofStockShelfRegistrationMaximumEquityOfferingPrice	175000000	USD
CY2018Q3	innt	Saleof Stock Stockholders Aggregate Shares Availableforsale SaleofStockStockholdersAggregateSharesAvailableforsale	13990403	shares
CY2019Q3	innt	Separation Agreements Number Of Former Executives SeparationAgreementsNumberOfFormerExecutives	2	executive
	innt	Severance Costs Equal Installment Period SeveranceCostsEqualInstallmentPeriod	P12M
CY2018Q1	innt	Severance Provisions Annual Base Salary Period SeveranceProvisionsAnnualBaseSalaryPeriod	P12M
CY2018Q1	innt	Severance Provisions Continuation Of Health Insurance Benefits Period SeveranceProvisionsContinuationOfHealthInsuranceBenefitsPeriod	P12M
CY2018Q1	innt	Stock Issued During Period Value Stock Splits StockIssuedDuringPeriodValueStockSplits	-978674	USD
CY2018Q2	innt	Stock Issued During Period Value Warrant Exercised StockIssuedDuringPeriodValueWarrantExercised	12472	USD
	innt	Writeoff Of Deferred Offering Costs WriteoffOfDeferredOfferingCosts	100056	USD
CY2018Q3	innt	Stock Issued During Period Value Warrant Exercised StockIssuedDuringPeriodValueWarrantExercised	828554	USD
CY2018Q4	innt	Warrant Liability Current WarrantLiabilityCurrent	0	USD
CY2019Q3	innt	Warrant Liability Current WarrantLiabilityCurrent	3188300	USD
CY2019Q2	innt	Warrants And Rights Outstanding Exercise Commencement Period WarrantsAndRightsOutstandingExerciseCommencementPeriod	P6M
	innt	Warrants Issued To Placement Agents WarrantsIssuedToPlacementAgents	913000	USD
	innt	Warrants Issued To Placement Agents WarrantsIssuedToPlacementAgents	0	USD
	innt	Writeoff Of Deferred Offering Costs WriteoffOfDeferredOfferingCosts	0	USD
CY2019Q3	innt	Writeoff Of Deferred Offering Costs WriteoffOfDeferredOfferingCosts	100000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3618634	USD
CY2019Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3056902	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	826327	USD
CY2019Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1863225	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	39854297	USD
CY2019Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	58341695	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	3077887	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7174000	USD
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	-184000	USD
CY2018Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	-3131000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	526000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	852000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	900000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	2568079	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	319819	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	389623	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Split AdjustmentsToAdditionalPaidInCapitalStockSplit	0	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	2000000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1995000	USD
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	-3131000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3859000	USD
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	900000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2278000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2060000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	713709	USD
CY2018Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9500000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9545736	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9500000	shares
CY2019Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	25600000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	25571927	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	25600000	shares
CY2018Q4	us-gaap	Assets Assets	6454188	USD
CY2019Q3	us-gaap	Assets Assets	9810209	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	6413513	USD
CY2019Q3	us-gaap	Assets Current AssetsCurrent	9719888	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5728900	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8863796	USD
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	28731934	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	355563	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8111682	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5728900	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8863796	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	7756119	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3134896	USD
CY2018Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	75000	USD
CY2019Q3	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	75000	USD
CY2019Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.13
CY2019Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	15120898	shares
CY2019Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	3897010	shares
CY2018Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	154403	shares
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	12981599	shares
CY2019Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2019Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26088820	shares
CY2019Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35883953	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26088820	shares
CY2019Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35883953	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	2609	USD
CY2019Q3	us-gaap	Common Stock Value CommonStockValue	3589	USD
CY2018Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	5196667	USD
CY2019Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	3875709	USD
CY2019Q3	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	200000	USD
CY2018Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	104706	USD
CY2019Q3	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0	USD
	us-gaap	Depreciation Depreciation	14417	USD
	us-gaap	Depreciation Depreciation	16104	USD
CY2018Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
CY2019Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	229000	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	881000	USD
CY2018Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	370000	USD
CY2019Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	770000	USD
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.82
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.26
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.56
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	697334	USD
CY2019Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	542214	USD
CY2018Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2019Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2528100	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-141700	USD
	us-gaap	Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	652700	USD
CY2018Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	370000	USD
CY2019Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	3958300	USD
CY2018Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2019Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1049166	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1000000	USD
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1565992	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8669455	USD
CY2019Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2564508	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8728714	USD
CY2018Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-775930	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19951226	USD
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9221232	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18144237	USD
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-754435	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-708219	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-878181	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1036898	USD
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	0	USD
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-511000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-101624	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	363738	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	276185	USD
CY2018Q3	us-gaap	Interest Expense InterestExpense	1038014	USD
	us-gaap	Interest Expense InterestExpense	5593751	USD
CY2019Q3	us-gaap	Interest Expense InterestExpense	472052	USD
	us-gaap	Interest Expense InterestExpense	1330923	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	175578	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	314721	USD
CY2018Q3	us-gaap	Interest Income Other InterestIncomeOther	42431	USD
	us-gaap	Interest Income Other InterestIncomeOther	127560	USD
CY2019Q3	us-gaap	Interest Income Other InterestIncomeOther	57848	USD
	us-gaap	Interest Income Other InterestIncomeOther	156945	USD
	us-gaap	Interest Paid Net InterestPaidNet	280287	USD
	us-gaap	Interest Paid Net InterestPaidNet	418927	USD
CY2018Q4	us-gaap	Interest Payable Current InterestPayableCurrent	101624	USD
CY2019Q3	us-gaap	Interest Payable Current InterestPayableCurrent	314721	USD
CY2018Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	15000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	45000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	60000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	45000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	15000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3725	USD
CY2019Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P2Y
CY2017Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P2Y
CY2017Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P3Y
CY2018Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P24M
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6454188	USD
CY2019Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9810209	USD
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	978674	USD
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	0	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10113252	USD
CY2019Q3	us-gaap	Liabilities Current LiabilitiesCurrent	13125132	USD
	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	3600000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20455760	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	17888682	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	61057	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9475	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12760698	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14744311	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-14959744	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-4215552	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-775930	USD
	us-gaap	Net Income Loss NetIncomeLoss	-19951226	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-4434765	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-4488240	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-9221232	USD
	us-gaap	Net Income Loss NetIncomeLoss	-18144237	USD
CY2018Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-995583	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5466191	USD
CY2019Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2713304	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1200444	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	-219653	USD
	us-gaap	Operating Expenses OperatingExpenses	14485035	USD
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	6507928	USD
	us-gaap	Operating Expenses OperatingExpenses	16943793	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-219653	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	14485035	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	6507928	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	16943793	USD
CY2019Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	56275	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	70842	USD
CY2019Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	15000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	45000	USD
CY2019Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	56275	USD
CY2019Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	52879	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5580	USD
CY2019Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5580	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	20000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	57000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1655079	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1045468	USD
CY2019Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	56275	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	100000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13943	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9475	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	504907	USD
CY2019Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	781092	USD
	us-gaap	Proceeds From Collection Of Longterm Loans To Related Parties ProceedsFromCollectionOfLongtermLoansToRelatedParties	75000	USD
	us-gaap	Proceeds From Collection Of Longterm Loans To Related Parties ProceedsFromCollectionOfLongtermLoansToRelatedParties	0	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	18100000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	18132661	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	20706919	USD
CY2019Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	9700000	USD
CY2019Q2	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	7900000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	3345000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	5000000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	30064	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	928178	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	35095	USD
CY2019Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	28466	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	275000	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	6745833	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	-1785645	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5815580	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3943420	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8215079	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-43515970	USD
CY2019Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-61660207	USD
CY2019Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	4181068	shares
CY2019Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	4318272	shares
	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	8499340	shares
CY2017Q4	us-gaap	Security Deposit SecurityDeposit	5000	USD
CY2019Q3	us-gaap	Severance Costs1 SeveranceCosts1	0	USD
	us-gaap	Severance Costs1 SeveranceCosts1	300000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3859000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2278000	USD
CY2019Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	2.33

Files In Submission

Name	View Source	Status
0001551986-19-000114-index-headers.html	Edgar Link	pending
0001551986-19-000114-index.html	Edgar Link	pending
0001551986-19-000114.txt	Edgar Link	pending
0001551986-19-000114-xbrl.zip	Edgar Link	pending
ex311q32019.htm	Edgar Link	pending
ex312q32019.htm	Edgar Link	pending
ex321q32019.htm	Edgar Link	pending
ex322q32019.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
innt-20190930.xml	Edgar Link	completed
innt-20190930.xsd	Edgar Link	pending
innt-20190930_cal.xml	Edgar Link	unprocessable
innt-20190930_def.xml	Edgar Link	unprocessable
innt-20190930_lab.xml	Edgar Link	unprocessable
innt-20190930_pre.xml	Edgar Link	unprocessable
innt930201910-q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

9 METERS BIOPHARMA, INC.

2019 Q4 Form 10-Q Financial Statement

#000155198619000114 Filed on November 07, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission